title: Evidence to support use of palonosetron over generic serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting.
authors.affiliation: Yu-Chen Yeh, M.S., B.S.Pharm., is Senior Pharmacist, Center for Drug Policy, Partners Healthcare, Needham, MA. Gayle C. Blouin, Pharm.D., BCOP, is Senior Attending Pharmacist and Clinical Lead-Ambulatory Oncology, Yawkey Center for Outpatient Care, Massachusetts General Hospital, Boston. Prabashni Reddy, Pharm.D., M.Med.Sc., is Director, Center for Drug Policy, Partners Healthcare.
authors.forename: Yu-Chen
authors.initials: YC
authors.lastname: Yeh
authors.forename: Gayle C
authors.initials: GC
authors.lastname: Blouin
authors.forename: Prabashni
authors.initials: P
authors.lastname: Reddy
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic / Q000379:methods; D016568:Drugs, Generic / Q000627:therapeutic use; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D000077924:Palonosetron; D011812:Quinuclidines / Q000627:therapeutic use*; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D016568:Drugs, Generic; D007546:Isoquinolines; D011812:Quinuclidines; D058831:Serotonin 5-HT3 Receptor Antagonists; D000077924:Palonosetron